Biomarin Pharmaceutical - Registered Shares Profit Margin

Biomarin Pharmaceutical - Registered Shares (BMRN) currently reports a profit margin of 8.29% as of March 2026. That compares with 14.47% in the prior-year period — down 42.7% year over year. That is below the Healthcare sector average of 15.29%. Use the charts on this page to explore Biomarin Pharmaceutical - Registered Shares's profit margin history and peer comparisons.

Biomarin Pharmaceutical - Registered Shares's profit margin decreased from 14.47% to 8.29% — a 42.7% year-over-year decrease (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Biomarin Pharmaceutical - Registered Shares's profit margin of 8.29% is lower than the Healthcare sector average of 15.29%. That is roughly 45.8% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Biomarin Pharmaceutical - Registered Shares's current 8.29% should be judged against Healthcare norms (sector average: 15.29%) and against BMRN's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of 8.29%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 15.29%. From there, open related valuation or income-statement pages for Biomarin Pharmaceutical - Registered Shares, and consider following BMRN for alerts when major investors trade the stock.